IGNT NEWS OUT

[RAZOR11]

YUCAIPA, Calif., Oct. 23, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that Medical Industries Australia has signed an OEM contract with Ingen.


Related Quotes
Symbol Price Change
IGNT.PK 0.0033 -0.0001


{"s" : "ignt.pk","k" : "c10,l10,p20,t10","o" : "","j" : ""}
Medical Industries Australia is a leading provider of sterile and non-sterile medical products, training and maintenance services, and provides high quality products and services to the Australian healthcare sector and has been supplying distributors and resellers, public and private hospitals, government departments, private clinics, aged care facilities and medical surgeries for more than 20 years.



In Australia, under the national Medicare health scheme, all interstitial lung disease and COPD patients who require oxygen therapy, are provided with a 5 liter/min oxygen concentrator at no cost, this includes a free Oxygen tubing & nasal cannula each month. State Government funded, the concentrators and consumables suppliers are selected by tender, usually on a 3+1 year arrangement.



In the case of new or innovative devices, such as Ingen's Oxyview Nasal Cannula, they fall outside the state tender and can be offered to public government-funded hospitals for trial and evaluation and if accepted, purchased by the various respiratory departments to be used by their patients. Approximately 1,000 COPD patients, each day, occupy a public hospital bed in Australia (at a cost of $580 per day). In many cases it's due to an exacerbation requiring a respiratory investigative review with new titration and oxygen therapy needs established. Approximately 30,000 patients use Oxygen concentrators on a daily basis.



"I look forward to working with Angus Taylor, CEO of Medical Industries Australia. He has already mentioned strong interest from local acute public hospitals in Sydney. We will commence product shipments upon completion of our ISO Certification and CE Mark expected in late December-2009," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.